Related Experiment Video

Updated: Feb 1, 2026

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
10:35

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

18.9K

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer

Liya Ding1, Hye-Jung Kim2, Qiwei Wang1

  • 1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.

Cell Reports
|December 13, 2018
PubMed

Insights

Olaparib, a PARP inhibitor, enhances antitumor immunity in BRCA-deficient ovarian tumors by activating STING. Combining olaparib with PD-1 blockade further boosts this immune response, offering new therapeutic strategies.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Poly (ADP-ribose) polymerase (PARP) inhibitors demonstrate clinical efficacy in BRCA-mutated cancers, particularly ovarian cancer.
  • The precise mechanisms by which PARP inhibition modulates the tumor microenvironment and host immune system are not fully understood.

Purpose of the Study:

  • To elucidate the molecular mechanisms of PARP inhibition in antitumor immunity.
  • To investigate the role of STING-dependent pathways in mediating the effects of olaparib.
  • To evaluate the synergistic potential of combining olaparib with PD-1 blockade.

Main Methods:

  • Utilized a mouse model of Brca1-deficient ovarian tumors.
  • Administered olaparib to assess its impact on antitumor immunity.
  • Investigated STING pathway activation.
  • Combined olaparib with PD-1 blockade to evaluate combination therapy efficacy.

Main Results:

  • Olaparib treatment induced significant local and systemic antitumor immune responses.
  • The observed immune activation was dependent on the STING pathway.
  • Combination therapy with olaparib and PD-1 blockade resulted in augmented antitumor effects.

Conclusions:

  • PARP inhibition with olaparib stimulates a STING-dependent antitumor immune response in ovarian cancer.
  • Combination of olaparib with PD-1 blockade enhances therapeutic outcomes.
  • These findings provide a mechanistic basis for improving cancer immunotherapy.
Keywords:
BRCA deficiencyGEMMPARP inhibitionPD-1 blockadeSTINGimmune responseimmunotherapyovarian cancertargeted therapy

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.2K
Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors09:22

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Published on: February 28, 2021

6.0K

Related Concept Videos

What is the Immune System?01:38

What is the Immune System?

Overview
127.9K
Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.1K
Frequency-dependent Selection01:21

Frequency-dependent Selection

When the fitness of a trait is influenced by how common it is (i.e., its frequency) relative to different traits within a population, this is referred to as frequency-dependent selection. Frequency-dependent selection may occur between species or within a single species. This type of selection can either be positive—with more common phenotypes having higher fitness—or negative, with rarer phenotypes conferring increased fitness.
24.0K
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.4K
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
3.9K
Humoral Immune Responses01:36

Humoral Immune Responses

Overview
83.9K